IL-1 Receptor-Associated Kinase Signaling and Its Role in Inflammation, Cancer Progression, and Therapy Resistance

Chronic inflammation has long been associated with the development of cancer. Among the various signaling pathways within cancer cells that can incite the expression of inflammatory molecules are those that activate IL-1 receptor-associated kinases (IRAK). The IRAK family is comprised of four family members, IRAK-1, IRAK-2, IRAK-3 (also known as IRAK-M), and IRAK-4, which play important roles in both positively and negatively regulating the expression of inflammatory molecules. The wide array of inflammatory molecules that are expressed in response to IRAK signaling within the tumor microenvironment regulate the production of factors which promote tumor growth, metastasis, immune suppression, and chemotherapy resistance. Based on published reports we propose that dysregulated activation of the IRAK signaling pathway in cancer cells contributes to disease progression by creating a highly inflammatory tumor environment. In this article, we present both theoretical arguments and reference experimental data in support of this hypothesis.

[1]  Lesley A. Mathews,et al.  Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. , 2013, Cancer cell.

[2]  M. Denison,et al.  Ginsenosides Are Novel Naturally-Occurring Aryl Hydrocarbon Receptor Ligands , 2013, PloS one.

[3]  E. Davila,et al.  TLR agonists: our best frenemy in cancer immunotherapy , 2013, Journal of leukocyte biology.

[4]  J. Qin,et al.  IRAK‐M mediates Toll‐like receptor/IL‐1R‐induced NFκB activation and cytokine production , 2013, The EMBO journal.

[5]  A. Leite-Moreira,et al.  Helicobacter pylori Induces Increased Expression of Toll‐Like Receptors and Decreased Toll‐Interacting Protein in Gastric Mucosa that Persists Throughout Gastric Carcinogenesis , 2013, Helicobacter.

[6]  Navneeta Bansal,et al.  Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4. , 2012, Cancer research.

[7]  B. Quesnel,et al.  MYD88 L265P mutation in Waldenstrom macroglobulinemia. , 2012, Blood.

[8]  N. Frangogiannis,et al.  Endogenous IRAK-M Attenuates Postinfarction Remodeling Through Effects on Macrophages and Fibroblasts , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[9]  Dong-Hyun Kim,et al.  Ginsenoside Re ameliorates inflammation by inhibiting the binding of lipopolysaccharide to TLR4 on macrophages. , 2012, Journal of agricultural and food chemistry.

[10]  S. Goerdt,et al.  Differentiation and gene expression profile of tumor-associated macrophages. , 2012, Seminars in cancer biology.

[11]  C. Pearce,et al.  Effects of (5Z)-7-oxozeaenol on MDA-MB-231 breast cancer cells. , 2012, Anticancer research.

[12]  I. Kovalszky,et al.  Tumor-produced, active Interleukin-1 β regulates gene expression in carcinoma-associated fibroblasts , 2011, Experimental cell research.

[13]  D. Melisi,et al.  Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. , 2011, Journal of the National Cancer Institute.

[14]  Dong-Hyun Kim,et al.  Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation--the key step of inflammation. , 2011, Biochemical pharmacology.

[15]  D. Carson,et al.  Role of IL-1 receptor-associated kinase-M (IRAK-M) in priming of immune and inflammatory responses by nitrogen bisphosphonates , 2011, Proceedings of the National Academy of Sciences.

[16]  P. Linsley,et al.  miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice , 2011, The Journal of experimental medicine.

[17]  S. Brandt,et al.  Induction of TLR-2 and TLR-5 Expression by Helicobacter pylori Switches cagPAI-Dependent Signalling Leading to the Secretion of IL-8 and TNF-α , 2011, PloS one.

[18]  S. Biswas,et al.  Impaired antigen presentation and potent phagocytic activity identifying tumor-tolerant human monocytes. , 2011, Biochemical and biophysical research communications.

[19]  J. Chiu,et al.  1,3,5-trihydroxy-4-prenylxanthone represses lipopolysaccharide-induced iNOS expression via impeding posttranslational modification of IRAK-1. , 2011, Biochemical pharmacology.

[20]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[21]  G. Stark,et al.  The Dual Functions of IL-1 Receptor-Associated Kinase 2 in TLR9-Mediated IFN and Proinflammatory Cytokine Production , 2011, The Journal of Immunology.

[22]  Joseph M. Connors,et al.  Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.

[23]  A. Bowie,et al.  The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. , 2010, Biochemical pharmacology.

[24]  R. Kuick,et al.  TGF-β-induced IRAK-M Expression in Tumor Associated Macrophages Regulates Lung Tumor Growth , 2010, Oncogene.

[25]  C. Mohan,et al.  Toll-Like Receptor Signaling Pathways—Therapeutic Opportunities , 2010, Mediators of inflammation.

[26]  Yuhai Zhao,et al.  Differential Regulation of Interleukin-1 Receptor-associated Kinase-1 (IRAK-1) and IRAK-2 by MicroRNA-146a and NF-κB in Stressed Human Astroglial Cells and in Alzheimer Disease* , 2010, The Journal of Biological Chemistry.

[27]  A. Jukkola-Vuorinen,et al.  Expression of toll‐like receptor‐9 is increased in poorly differentiated prostate tumors , 2010, The Prostate.

[28]  Zhiwei Wang,et al.  miR-146a suppresses invasion of pancreatic cancer cells. , 2010, Cancer research.

[29]  Zhenjun Wu,et al.  Selective up-regulation of CDK2 is critical for TLR9 signaling stimulated proliferation of human lung cancer cell. , 2010, Immunology letters.

[30]  R. Lotan,et al.  Expression of Interleukin-1 Receptor–Associated Kinase-1 in Non–Small Cell Lung Carcinoma and Preneoplastic Lesions , 2009, Clinical Cancer Research.

[31]  N. Walker,et al.  IRAK-4 Inhibitors for Inflammation , 2009, Current topics in medicinal chemistry.

[32]  P. Cohen.  Targeting protein kinases for the development of anti-inflammatory drugs. , 2009, Current opinion in cell biology.

[33]  Ya Zhou,et al.  TLR9 Signaling Promotes Tumor Progression of Human Lung Cancer Cell In Vivo , 2009, Pathology & Oncology Research.

[34]  Kedar S Vaidya,et al.  Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. , 2009, Cancer research.

[35]  L. O’Neill,et al.  The interleukin‐1 receptor/Toll‐like receptor superfamily: 10 years of progress , 2008, Immunological reviews.

[36]  S. Schokrpur,et al.  Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells , 2008, Oncogene.

[37]  A. Jukkola-Vuorinen,et al.  Toll-Like Receptor-9 Expression Is Inversely Correlated with Estrogen Receptor Status in Breast Cancer , 2008, Journal of Innate Immunity.

[38]  A. Bowie.  Insights from vaccinia virus into Toll-like receptor signalling proteins and their regulation by ubiquitin: role of IRAK-2. , 2008, Biochemical Society transactions.

[39]  Osamu Takeuchi,et al.  Sequential control of Toll-like receptor–dependent responses by IRAK1 and IRAK2 , 2008, Nature Immunology.

[40]  J. Ashwell,et al.  Lys63-Linked Polyubiquitination of IRAK-1 Is Required for Interleukin-1 Receptor- and Toll-Like Receptor-Mediated NF-κB Activation , 2008, Molecular and Cellular Biology.

[41]  Navin L Rao,et al.  IRAK1: a critical signaling mediator of innate immunity. , 2008, Cellular signalling.

[42]  Jeong-Won Lee,et al.  Increased toll‐like receptor 9 expression in cervical neoplasia , 2007, Molecular carcinogenesis.

[43]  K. Tracey,et al.  HMGB1 SIGNALS THROUGH TOLL-LIKE RECEPTOR (TLR) 4 AND TLR2 , 2006, Shock.

[44]  E. Abraham,et al.  High mobility group box 1 protein interacts with multiple Toll-like receptors. , 2006, American journal of physiology. Cell physiology.

[45]  W. Fung-Leung,et al.  A Novel Splice Variant of Interleukin-1 Receptor (IL-1R)-Associated Kinase 1 Plays a Negative Regulatory Role in Toll/IL-1R-Induced Inflammatory Signaling , 2005, Molecular and Cellular Biology.

[46]  Linda N. Lee,et al.  The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides. , 2005, Journal of immunological methods.

[47]  Felipe García,et al.  Tumor Cells Deactivate Human Monocytes by Up-Regulating IL-1 Receptor Associated Kinase-M Expression via CD44 and TLR41 , 2005, The Journal of Immunology.

[48]  Johannes Gerdes,et al.  Human lung cancer cells express functionally active Toll-like receptor 9 , 2005, Respiratory research.

[49]  P. Fisher,et al.  Identification and cloning of genes displaying elevated expression as a consequence of metastatic progression in human melanoma cells by rapid subtraction hybridization. , 2004, Gene.

[50]  P. Cao,et al.  Sequential Autophosphorylation Steps in the Interleukin-1 Receptor-associated Kinase-1 Regulate its Availability as an Adapter in Interleukin-1 Signaling* , 2004, Journal of Biological Chemistry.

[51]  V. Ambros.  MicroRNA Pathways in Flies and Worms Growth, Death, Fat, Stress, and Timing , 2003, Cell.

[52]  J. Banchereau,et al.  Pyogenic Bacterial Infections in Humans with MyD88 Deficiency , 2003, Science.

[53]  A. Al-ghonaium,et al.  Pyogenic Bacterial Infections in Humans with IRAK-4 Deficiency , 2003, Science.

[54]  Charles A. Janeway,et al.  IRAK-M Is a Negative Regulator of Toll-like Receptor Signaling , 2002, Cell.

[55]  T. Mak,et al.  Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4 , 2002, Nature.

[56]  Holger Wesche,et al.  IRAK-4: A novel member of the IRAK family with the properties of an IRAK-kinase , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[57]  A. Whitehead,et al.  IRAK1b, a Novel Alternative Splice Variant of Interleukin-1 Receptor-associated Kinase (IRAK), Mediates Interleukin-1 Signaling and Has Prolonged Stability* , 2001, The Journal of Biological Chemistry.

[58]  Liwu Li,et al.  Characterization of Interleukin-1 Receptor-associated Kinase in Normal and Endotoxin-tolerant Cells* , 2000, The Journal of Biological Chemistry.

[59]  J. Swantek,et al.  IL-1 Receptor-Associated Kinase Modulates Host Responsiveness to Endotoxin1 , 2000, The Journal of Immunology.

[60]  G. Stark,et al.  IRAK-M Is a Novel Member of the Pelle/Interleukin-1 Receptor-associated Kinase (IRAK) Family* , 1999, The Journal of Biological Chemistry.

[61]  Douglas K. Miller,et al.  The Interleukin-1 Receptor-associated Kinase Is Degraded by Proteasomes following Its Phosphorylation* , 1997, The Journal of Biological Chemistry.

[62]  Craig R Moores,et al.  H-40, an antigen controlled by an Igh linked gene and recognized by cytotoxic T lymphocytes. I. Genetic analysis of H-40 and distribution of its product on B cell tumors , 1984, The Journal of experimental medicine.

[63]  Simone Gritsch.  next generation , 2011, Electric and Hybrid Rail Technology.

[64]  Hong Wang,et al.  Critical Reviews in Oral Biology & Medicine: TLR-signaling Networks: An Integration of Adaptor Molecules, Kinases, and Cross-talk , 2011 .